Rifampin Regimen for Latent Tuberculosis Infection – CDC/National TB Controllers Association Guidelines
Recommended Regimen
- For adults with latent TB infection who have normal liver function, no rifamycin hypersensitivity, and no relevant drug interactions, the CDC recommends a 4‑month course of daily rifampin 10 mg/kg (maximum 600 mg) taken orally once daily either ≥ 1 hour before or ≥ 2 hours after meals with a full glass of water. Strong recommendation; moderate‑quality evidence for HIV‑negative adults. [1][2]
Evidence Strength & Preferred Status
- The 4‑month rifampin regimen is classified as a preferred treatment option in the CDC/National TB Controllers Association 2020 guidelines, alongside 3 months of weekly isoniazid‑rifapentine and 3 months of daily isoniazid‑rifampin. Strong recommendation. [1][2]
Duration Compared with Isoniazid Regimens
- The rifampin regimen’s duration (4 months) is shorter than the typical 6‑9 months required for isoniazid‑based latent TB therapy. Strong recommendation. [1][2]
Drug‑Interaction Considerations
- Rifampin induces hepatic enzymes and therefore has extensive drug‑interaction potential, especially with warfarin, oral contraceptives, azole antifungals, and antiretroviral agents. Strong recommendation to assess these interactions before initiating therapy. [1][3]
Alternative Regimens When Significant Interactions Exist
- Weekly isoniazid‑rifapentine (3 months) – recommended when rifampin‑related drug interactions are likely; it has fewer interactions. Strong recommendation. [1][2]
- Rifabutin substitution – an alternative rifamycin with a lower interaction profile. Strong recommendation. [1][3]
- Isoniazid alone (6‑9 months) – advised if any rifamycin cannot be used. Strong recommendation. [1][2]
Special Population: Persons Living with HIV
- The 4‑month rifampin regimen has a strong recommendation with moderate‑quality evidence for HIV‑negative adults but lacks evidence in HIV‑positive individuals. For HIV‑positive patients, a conditional recommendation with low‑quality evidence supports 3 months of isoniazid‑rifampin, or the use of alternative regimens with established efficacy in this group. [1][2]